Pharma Faces $200-300 Billion Patent Cliff Through 2032 as Blockbusters Lose Exclusivity
The global biopharmaceutical industry entered 2026 facing one of the largest waves of patent expirations in its history, with $200-300 billion in yearly sales at risk through 2032 as major drugs lose exclusivity.